GLP1R and metabolic dysfunction-associated steatotic liver disease: Moreover, gut microbiota analysis found that liraglutide, a GLP-1 receptor agonist, could modify gut microbiota diversity by decreasing the abundance of Proteobacteria and increasing the level of Akkermansia muciniphila, which was associated with the improvement of NAFLD [72].